{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:59:23Z","timestamp":1785394763784,"version":"3.55.0"},"reference-count":137,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cancer patients have an increased risk of cardiovascular disease and, notably, a significant prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence of cardiovascular risk factors in this setting leads to an interaction between these two conditions, influencing their therapeutic strategies and contributing to higher mortality. Nonetheless, cancer patients have generally not been evaluated in ACS trials, so that the treatment in these cases is still not fully known. We reviewed the current literature and discussed the best management for these very high-risk patients. The treatment strategy must be tailored based on the cancer type and stage, balancing thrombotic and bleeding risks. When the prognosis is longer than six months, especially if a clinical instability coexists, patients with ACS and cancer should be referred for percutaneous coronary intervention (PCI) as soon as possible. Moreover, an invasive strategy should be preferred in STEMI patients as well as in NSTEMI patients who are considered as high risk. On the contrary, in clinically stable NSTEMI patients, a conservative non-invasive strategy could be adopted, especially in cases of a poor life expectancy and\/or of high risk of bleeding. Drug-Eluting-Stents (DES) should be the first choice if an invasive strategy is adopted. Conservative therapy could instead be considered in cancer patients with more stable CAD at an increased risk of major bleeding complications. However, the duration of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is recommended, but it should be as short as possible, whereas triple antithrombotic therapy is non-advised because it significantly increases the risk of bleeding. ACS management among cancer patients should be based on an accurate evaluation of the risk of thrombosis and bleeding. Future studies focused on choosing optimal strategies in tumor patients with ACS should be performed to treat this subset of patients better.<\/jats:p>","DOI":"10.3390\/jcm11071792","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T21:27:51Z","timestamp":1648416471000},"page":"1792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Management of Acute Coronary Syndrome in Cancer Patients: It\u2019s High Time We Dealt with It"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-5382","authenticated-orcid":false,"given":"Fabiana","family":"Luc\u00e0","sequence":"first","affiliation":[{"name":"Cardiology Department, Grande Ospedale Metropolitano, AO Bianchi Melacrino Morelli, 89129 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Parrini","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Mauriziano Umberto I, 10128 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-7157","authenticated-orcid":false,"given":"Maurizio Giuseppe","family":"Abrignani","sequence":"additional","affiliation":[{"name":"Cardiology Department, P.O. S. Antonio Abate, 91100 Trapani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo Massimiliano","family":"Rao","sequence":"additional","affiliation":[{"name":"Cardiology Department, Grande Ospedale Metropolitano, AO Bianchi Melacrino Morelli, 89129 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piccioni","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale \u201cG. Mazzini\u201d, 64100 Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Department, Presidio Ospedaliero San Filippo Neri, ASL Roma 1, 10128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Lamezia Terme, 88046 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[{"name":"Integrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, A.O.R.N. Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-989X","authenticated-orcid":false,"given":"Sandro","family":"Gelsomino","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, Maastricht University, 6221 Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Department, Presidio Ospedaliero San Filippo Neri, ASL Roma 1, 10128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[{"name":"Cardiology Department, Azienda di Rilievo Nazionale e Alta Specializzazione \u201cGaribaldi\u201d, 95126 Catania, Italy"},{"name":"Fondazione per il Tuo Cuore-Heart Care Foundation, 50121 Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jnci\/djn310","article-title":"Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study","volume":"100","author":"Mertens","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/2048872617729636","article-title":"Treatment of patients with myocardial infarction depends on history of cancer","volume":"7","author":"Rohrmann","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.mayocp.2016.06.029","article-title":"Cancer History Portends Worse Acute and Long-term Noncardiac (but Not Cardiac) Mortality after Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction","volume":"91","author":"Wang","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ehjacc\/zuab056","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: A Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology\u2014Part 1: Acute coronary syndromes and acute pericardial diseases","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/2048872617706501","article-title":"Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: A BleeMACS substudy","volume":"7","author":"Iannaccone","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S2215-0366(16)30377-7","article-title":"Post-traumatic stress disorder and cardiovascular disease","volume":"4","author":"Edmondson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0038-1623532","article-title":"Global Geriatric Assessment and In-Hospital Bleeding Risk in Elderly Patients with Acute Coronary Syndromes: Insights from the LONGEVO-SCA Registry","volume":"118","author":"Guerrero","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2015.12.048","article-title":"Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes with Early Implementation of the ACC\/AHA Guidelines Risk Score to Predict In-Hospital Mortality and Major Bleeding in Acute Coronary Syndromes","volume":"117","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2018.05.024","article-title":"Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry","volume":"167","author":"Guerrero","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1093\/eurheartj\/ehz645","article-title":"Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11864-019-0644-3","article-title":"Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges","volume":"20","author":"Das","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2459\/JCM.0000000000000993","article-title":"Acute coronary syndromes in cancer patients","volume":"21","author":"Bisceglia","year":"2020","journal-title":"J. Cardiovasc. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Radmilovic, J., Di Vilio, A., D\u2019Andrea, A., Pastore, F., Forni, A., Desiderio, A., Ragni, M., Quaranta, G., Cimmino, G., and Russo, V. (2020). The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123926"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared Risk Factors in Cardiovascular Disease and Cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.21873\/anticanres.13642","article-title":"Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels","volume":"39","author":"Canale","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: A common contributor to cancer, aging, and cardiovascular diseases\u2014Expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMp030086","article-title":"Cancer-Associated Thrombosis","volume":"349","author":"Bick","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-2006-933341","article-title":"Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy","volume":"32","author":"Rak","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2017.07.719","article-title":"Cancer and Clot: Between a Rock and a Hard Place","volume":"70","author":"Yeh","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2015.07.001","article-title":"The prothrombotic activity of cancer cells in the circulation","volume":"30","author":"Mitrugno","year":"2015","journal-title":"Blood Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11886-017-0862-x","article-title":"Management of CAD in Patients with Active Cancer: The Interventional Cardiologists\u2019 Perspective","volume":"19","author":"Giza","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients with Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2018.10.008","article-title":"Acute coronary syndromes in patients with active hematologic malignancies\u2014Incidence, management, and outcomes","volume":"275","author":"Park","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal Therapy Use for Prostate Cancer and Mortality in Men with Coronary Artery Disease\u2013Induced Congestive Heart Failure or Myocardial Infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study","volume":"10","author":"Jaillais","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0828-282X(06)70905-9","article-title":"Acute coronary syndrome induced by oral capecitabine","volume":"22","author":"Cardinale","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-Associated Cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High Incidence of Thromboembolic Events in Patients Treated with Cisplatin-Based Chemotherapy: A Large Retrospective Analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular Toxicities of Cancer Therapies: The Old and the New\u2014An Evolving Avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular Complications of Novel Multiple Myeloma Treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","article-title":"Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention","volume":"20","author":"Lee","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"652186","DOI":"10.3389\/fcvm.2021.652186","article-title":"Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients","volume":"8","author":"Inno","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-04-2624","article-title":"Antiangiogenic Concentrations of Paclitaxel Induce an Increase in Microtubule Dynamics in Endothelial Cells but Not in Cancer Cells","volume":"65","author":"Pasquier","year":"2005","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10245332.2017.1328165","article-title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: Practical management aspects from two case studies","volume":"22","author":"Jakubowiak","year":"2017","journal-title":"Hematology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women with Breast Cancer: A Population-Based Cohort Study","volume":"141","author":"Filion","year":"2020","journal-title":"Circulation"},{"key":"ref_48","first-page":"1783","article-title":"Capecitabine-induced cardiotoxicity: More evidence or clinical approaches to protect the patients\u2019 heart?","volume":"7","author":"Fontanella","year":"2014","journal-title":"OncoTargets Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hilmi, M., Ederhy, S., Waintraub, X., Funck-Brentano, C., Cohen, A., Vozy, A., Lebrun-Vignes, B., Moslehi, J., Nguyen, L.S., and Salem, J.-E. (2020). Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100325"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000504664","article-title":"Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors","volume":"64","author":"Santoro","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis of More Than 20,000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","article-title":"Sorafenib Cardiotoxicity Increases Mortality after Myocardial Infarction","volume":"114","author":"Duran","year":"2014","journal-title":"Circ. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis","volume":"20","author":"Autorino","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1074248418769612","article-title":"The Impact of Pazopanib on the Cardiovascular System","volume":"23","author":"Justice","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e12705","DOI":"10.1097\/MD.0000000000012705","article-title":"Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1177\/1078155220909422","article-title":"Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma","volume":"26","author":"Tanriverdi","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2146\/ajhp150188","article-title":"Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies","volume":"73","author":"Grabowski","year":"2016","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/1389557511313040006","article-title":"Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors","volume":"13","author":"Sharma","year":"2013","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/ehf2.13365","article-title":"Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications","volume":"8","author":"Bikiewicz","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_61","first-page":"115386","article-title":"Molecular docking analyses of Escin as regards cyclophosphamide-induced cardiotoxicity: In vivo and in Silico studies","volume":"411","author":"Cengiz","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"692970","DOI":"10.3389\/fphar.2021.692970","article-title":"Cardiovascular Toxicity Induced by Chronic Vincristine Treatment","volume":"12","author":"Uranga","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fphar.2017.00196","article-title":"Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments","volume":"8","author":"Uranga","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.12775\/JEHS.2021.11.06.033","article-title":"Cumulative cardiotoxic effect of bleomycin in experiment","volume":"11","author":"Gozhenko","year":"2021","journal-title":"J. Educ. Health Sport"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-Associated Cardiac Disease: A Practical Approach to Diagnosis and Management","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e021686","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology","volume":"10","author":"Eisenberg","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-Related Heart Disease: Current Knowledge and Future Prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0146645314560688","article-title":"Threshold doses and circulatory disease risks","volume":"44","author":"Hendry","year":"2015","journal-title":"Ann. ICRP"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.icrp.2012.06.031","article-title":"Mechanisms and dose-response relationships for radiation-induced cardiovascular disease","volume":"41","author":"Stewart","year":"2012","journal-title":"Ann. ICRP"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jacc.2016.06.027","article-title":"Takotsubo Stress Cardiomyopathy","volume":"68","author":"Munoz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-018-0724-8","article-title":"Acute Coronary Syndrome Management in Cancer Patients: \u201cGood News\u201d in Cancer Patients?","volume":"20","author":"Tsitlakidou","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: A report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.amjcard.2019.07.015","article-title":"Percutaneous Coronary Intervention and Outcomes in Patients with Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis)","volume":"124","author":"Borovac","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ccd.28432","article-title":"Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: A nationwide analysis","volume":"96","author":"Potts","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ehjacc\/zuaa032","article-title":"Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: A propensity score matching analysis","volume":"10","author":"Mohamed","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e13476","DOI":"10.1111\/ijcp.13476","article-title":"Management strategies and clinical outcomes of acute myocardial infarction in leukaemia patients: Nationwide insights from United States hospitalisations","volume":"74","author":"Mohamed","year":"2020","journal-title":"Int. J. Clin. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e18972","DOI":"10.1097\/MD.0000000000018972","article-title":"Clinical presentation and treatment of acute coronary syndrome as well as 1-year survival of patients hospitalized due to cancer: A 7-year experience of a nonacademic center","volume":"99","author":"Styczkiewicz","year":"2020","journal-title":"Medicine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.17219\/acem\/110316","article-title":"Acute coronary syndrome in patients undergoing anticancer therapies: A single-center, controlled case study","volume":"28","author":"Abdulaziz","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2020.04.050","article-title":"Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management","volume":"313","author":"Balanescu","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"620857","DOI":"10.3389\/fcvm.2021.620857","article-title":"Machine Learning-Augmented Propensity Score Analysis of Percutaneous Coronary Intervention in Over 30 Million Cancer and Non-cancer Patients","volume":"8","author":"Monlezun","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiolog\u0131a intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"394740","DOI":"10.4061\/2011\/394740","article-title":"Arterial and Venous Thrombosis in Cancer Patients","volume":"2011","author":"Blann","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry","volume":"53","author":"Heestermans","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/ehjqcco\/qcx047","article-title":"Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: A Kumamoto University Malignancy and Atherosclerosis (KUMA) study","volume":"4","author":"Tabata","year":"2017","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_91","first-page":"200","article-title":"Influence of a history of cancer on long-term cardiovascular outcomes after coronary stent implantation (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)","volume":"4","author":"Nakatsuma","year":"2018","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14779072.2020.1718493","article-title":"Outcomes of percutaneous coronary interventions in cancer patients","volume":"18","author":"Bharadwaj","year":"2020","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e014383","DOI":"10.1161\/JAHA.119.014383","article-title":"Temporal Trends in the Prevalence of Cancer and Its Impact on Outcome in Patients with First Myocardial Infarction: A Nationwide Study","volume":"9","author":"Velders","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.gie.2010.06.051","article-title":"Management of bleeding GI tumors","volume":"72","author":"Heller","year":"2010","journal-title":"Gastrointest. Endosc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehaa1032","article-title":"Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA","volume":"42","author":"Kwok","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2152\/jmi.68.29","article-title":"Prognostic Impact of Cancer Activity on Clinically Relevant Bleeding Events after Percutaneous Coronary Intervention","volume":"68","author":"Nishikawa","year":"2021","journal-title":"J. Med. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2217\/fon-2017-0543","article-title":"Statins use and cancer: An update","volume":"14","author":"Zaleska","year":"2018","journal-title":"Futur. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and Outcomes of Acute Coronary Syndrome in the Cancer Population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes","volume":"109","author":"Sarkiss","year":"2006","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients with Acute Coronary Syndrome and Chronic Thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(20)30222-1","article-title":"Cancer and cardiovascular disease","volume":"395","author":"Alam","year":"2020","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1002\/cncr.31696","article-title":"Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: A report from adult life after childhood cancer in Scandinavia","volume":"124","author":"Winther","year":"2018","journal-title":"Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pcad.2010.06.004","article-title":"Managing Coronary Artery Disease in the Cancer Patient","volume":"53","author":"Krone","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","article-title":"Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities","volume":"29","author":"Guha","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-020-01409-8","article-title":"Management of Patients with Acute Coronary Syndrome and Cancer","volume":"22","author":"Moran","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline Risk of Major Bleeding in Non\u2013ST-Segment\u2013Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jcin.2013.03.020","article-title":"Enhanced Mortality Risk Prediction with a Focus on High-Risk Percutaneous Coronary Intervention: Results From 1,208,137 Procedures in the NCDR (National Cardiovascular Data Registry)","volume":"6","author":"Brennan","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1093\/eurheartj\/ehs295","article-title":"Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: The Logistic Clinical SYNTAX score","volume":"33","author":"Farooq","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2008.08.026","article-title":"The Toronto score for in-hospital mortality after percutaneous coronary interventions","volume":"157","author":"Chowdhary","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijcard.2016.02.085","article-title":"A contemporary risk model for predicting 30-day mortality following percutaneous coronary intervention in England and Wales","volume":"210","author":"McAllister","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Milazzo, V., Cosentino, N., Campodonico, J., Lucci, C., Cardinale, D., Cipolla, C.M., and Marenzi, G. (2020). Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113642"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ijcard.2012.11.009","article-title":"Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients","volume":"167","author":"Kurisu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.amjcard.2013.08.019","article-title":"Outcome after ST Elevation Myocardial Infarction in Patients with Cancer Treated with Primary Percutaneous Coronary Intervention","volume":"112","author":"Velders","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MCA.0000000000000429","article-title":"Long-term outcomes after percutaneous coronary interventions in cancer survivors","volume":"28","author":"Landes","year":"2017","journal-title":"Coron. Artery Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2017","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jacc.2016.05.085","article-title":"Outcomes of Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","volume":"68","author":"Sutton","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacc.2021.11.034","article-title":"Patients with Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter?","volume":"79","author":"Vranckx","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e819","DOI":"10.1016\/j.amjmed.2016.01.041","article-title":"Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study","volume":"129","author":"Alotaibi","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy","volume":"139","author":"Lijfering","year":"2019","journal-title":"Circulation"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of Bleeding with Single, Dual, or Triple Therapy with Warfarin, Aspirin, and Clopidogrel in Patients with Atrial Fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy","volume":"34","author":"Coppens","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation: The HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) Score","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: A derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk","volume":"373","author":"Urban","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): A randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA J. Am. Med Assoc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:42:20Z","timestamp":1760136140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":137,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11071792"],"URL":"https:\/\/doi.org\/10.3390\/jcm11071792","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}